Sernova Biotherapeutics Inc (TSX:SVA)
Canada
· Delayed Price · Currency is CAD 0.1650
0.00 (0.00%)
Jun 24, 2025, 11:15 AM EDT
Sernova Biotherapeutics Employees
Sernova Biotherapeutics had 17 employees as of October 31, 2024.
Employees
17
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-1.37M CAD
Market Cap
54.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sienna Senior Living | 12,263 |
| dentalcorp Holdings | 10,200 |
| Green Thumb Industries | 4,800 |
| Extendicare | 23,000 |
| Cronos Group | 459 |
| WELL Health Technologies | 1,507 |
| Trulieve Cannabis | 6,000 |
| Curaleaf Holdings | 5,519 |
Sernova Biotherapeutics News
- 22 days ago - Sernova Appoints Jonathan Rigby as Interim Chair - GlobeNewsWire
- 4 weeks ago - Chair of Sernova Biotherapeutics Resigns - GlobeNewsWire
- 4 weeks ago - Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes - GlobeNewsWire
- 5 weeks ago - Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes - GlobeNewsWire
- 2 months ago - Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans - GlobeNewsWire
- 2 months ago - Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med - GlobeNewsWire
- 3 months ago - Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes - GlobeNewsWire
- 3 months ago - Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D - GlobeNewsWire